Previous 10 | Next 10 |
On May 11 after the market closed, AcelRx Pharmaceuticals (NASDAQ: ACRX ) reported 1Q20 earnings. The stock did not move much from the event, but investors that have been following the company for some time now finally got a piece of news they had been waiting for. ACRX is a specialty phar...
Merger activity remained stuck in neutral last week with no new deals announced and no deals closing. We did have one deal enter into litigation, and arbitrageurs are watching it closely to see if the courts can force the acquiring company to close the deal on the original terms. There were ...
I have covered AcelRx Pharmaceuticals ( ACRX ) before, so investors should view this as an update to my previous articles . Last summer, some readers may have watched a documentary about the race to the moon. I did, and one thing that I keep remembering is the pictures of the large lunar ...
The board of Tetraphase Pharmaceuticals (NASDAQ: TTPH ) has determined that the recent acquisition offer of up to $39.5M in upfront cash and a potential CVR payout from Melinta Therapeutics (NASDAQ: MLNT ) is superior to the previously-agreed-to all-stock deal valued at ~$14.4M fr...
3 Penny Stocks Turning Heads Right Now But Do Analysts Rate Them A “Buy” or “Sell? You don’t normally think about penny stocks and analyst ratings all the time. But just like any other public company, early-stage, small- and micro-cap companies garner analyst atte...
Tetraphase Pharmaceuticals (NASDAQ: TTPH ) discloses that it received an unsolicited bid yesterday from Melinta Therapeutics (NASDAQ: MLNT ) for $27.0M in cash plus an additional $12.5M payable under a contingent value right (CVR). More news on: Tetraphase Pharmaceuticals, Inc., Melinta ...
Myriad Receives the FDA Approval for Testing Ovarian Cancer Myriad Genetics ( MYGN ) announced that the FDA has given green signal to its myChoice CDx test to be used as a companion diagnostic for the identification of advanced ovarian cancer patients. The company stated that the device...
Genfit SA (NASDAQ: GNFT ) -67% after elafibranor flunks NASH study. More news on: Genfit SA, California Resources Corporation, Rand Capital, Stocks on the move, , Read more ...
Image source: The Motley Fool. AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
AcelRx Pharmaceuticals, Inc. (ACRX) Q1 2020 Results Earnings Conference Call May 11, 2020, 04:30 PM ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pamela Palmer - Chief Medical Officer and Co-Founder Christian Tvetenstrand - Chairman of Surgery & Director...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...